bluuebunny/crossref_metadata_2025_split huggingface dataset:
Haptoglobin Concentration, Pregnancy, and Preeclampsia in Women with Type 1 Diabetes
Authors: KELLY CLARE B. , YU JEREMY , JENKINS ALICIA , NANKERVIS ALISON J. , HANSSEN KRISTIAN F. , GARG SATISH K. , ASTON CHRISTOPHER E. , LYONS TIMOTHY 
Published: June 2018

Haptoglobin (Hp) binds the globin portion of free haemoglobin (Hb) thus inhibiting oxidative damage: it also has anti-inflammatory and pro-angiogenic properties. There are two Hp alleles and three phenotypes, Hp 1-1, Hp 2-1, and Hp 2-2; the latter is present in ∼50% of people, and is associated with cardiovascular risk and declining renal function in diabetes patients. Preeclampsia (PE) occurs more frequently in diabetic than nondiabetic women (∼20% vs. ∼5%): reasons are not fully elucidated, but oxidative stress, inflammation, and altered angiogenesis are implicated.
We determined maternal plasma Hp levels (ELISA, R and D Systems) and Hp phenotype (ELISA, Savyon Diagnostics Ltd.) in a prospective study of 23 pregnant women with type 1 diabetes (T1D) who developed PE, 24 who remained normotensive, and 19 pregnant normotensive nondiabetic women. Samples were collected at 3 visits (V1-V3) (12.4 ± 1.8, 21.7 ± 1.4, and 31.3 ± 1.4 weeks gestation (mean ± SD)). All subjects were free of microalbuminuria and hypertension at enrolment, and all visits preceded clinical PE onset.
Results: Longitudinal analyses revealed significant temporal decreases of plasma Hp during pregnancy in T1D women who developed PE (p=0.001) and in nondiabetic normotensive women (p=0.017), but not in T1D who remained normotensive. Among all T1D women, plasma Hp was lower in those with Hp 2-2 vs. ’non-Hp 2-2’ phenotype at V2 (p=0.005) and V3 (p=0.002), independent of PE status. In Hp 2-2 T1D women only, plasma Hp was higher in those who did vs. did not develop PE at V1 (77.0 ± 31.4 vs. 50.7 ± 14.5 (mg/dl)) (p=0.033) and V2 (61.9 ± 19.0 vs. 42.0 ± 21.5) (p=0.046). Plasma Hp correlated positively with CRP at all visits (p&lt;0.01), but not with previously-measured anti-angiogenic/angiogenic factors.
Conclusion: Maternal plasma Hp may serve as an early marker for PE in T1D pregnancy, particularly in women with the Hp 2-2 phenotype.

Disclosure
C.B. Kelly: None. J. Yu: None. A. Jenkins: Research Support; Self; Medtronic, Mylan, Sanofi-Aventis. A.J. Nankervis: None. K.F. Hanssen: None. S.K. Garg: Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Sanofi US. Advisory Panel; Self; Sanofi US. Research Support; Self; MannKind Corporation, Diasome Pharmaceuticals, Inc., Labstyle Innovations, Lexicon Pharmaceuticals, Inc., Medtronic. Advisory Panel; Self; Novo Nordisk A/S. C.E. Aston: None. T. Lyons: None.
IRS1 Is a Target of MicroRNA-126
Authors: TRYGGESTAD JEANIE B. , TEAGUE APRIL M. , CHERNAUSEK STEVEN 
Published: June 2018

Exposure to diabetes in utero has been shown to program offspring toward cardiometabolic disease and diabetes (DM). Alteration of fetal microRNA expression is a potential mechanism that mediates the effects of maternal conditions on the fetus. In previous work, we have shown that miRNA-126 expression is increased in umbilical vein endothelial cells (HUVEC) and in cord blood from infants born to mothers with DM. In this study we evaluated the capacity of miRNA-126 to target IRS1 mRNA by binding to a complementary sequence in the 3’UTR. A commercially available plasmid (SwitchGear Genomics) containing the 3’UTR of IRS1 with a luciferase reporter was co-transfected along with miRNA-126 into HEK-293A cells. Luciferase expression was reduced by 1.5-fold with the addition of miR-126 as compared to the controls (Figure 1). As confirmation, the sequence predicted to target miR-126 was cloned from HUVEC into the pmirGLO vector (Promega) also containing luciferase reporter. With the addition of miR-126, luciferase expression was reduced by 2.2-fold. The data suggest that IRS1 is a target for miR-126. As miR-126 is increased in HUVEC of infants born to mothers with DM, we postulate that IRS1 protein will be decreased, potentially impacting downstream signaling within the cell, as well as endothelial function. Future studies are planned to evaluate the impact of miR-126 on endothelial function.

Disclosure
J.B. Tryggestad: None. A.M. Teague: None. S. Chernausek: Advisory Panel; Self; Novo Nordisk Inc..
Budget Impact Analysis of Self-Monitoring of Blood Glucose vs. Flash-Continuous Glucose Monitoring in Intensive Insulin Users with Diabetes Type 2 Covered by Medicare and Medicaid
Authors: STUEVE MAGNUS , ZOELLNER YORK F. 
Published: June 2018

Introduction: Self-Monitoring of Blood Glucose (SMBG) uses capillary blood glucose to measure glycemia in diabetic patients. Recently FDA-approved Flash Continuous Glucose Monitoring (F-CGM) reveals glucose levels when scanned by the reading device. The Centers for Medicare and Medicaid Services (CMS) have announced to reimburse F-CGM at the same level as CGM devices.
Aim: This analysis’ objective was to quantify the CMS budget impact (BI) of F-CGM reimbursement in patients with type 2 diabetes (T2DM) on intensified insulin therapy (IIT), and compare it to the BI of conventional SMBG via cost-related break-even metrics. These were chosen because - in the absence of RCT-based, primary endpoint-driven clinical superiority evidence of F-CGM over SMBG for this population (REPLACE study) - they are well-suited to inform budget allocation decisions.
Methods: An economic model was developed in Excel. CMS reimbursement/patient co-insurance levels for SMBG and F-CGM were used; data on morbidity, treatment and usage patterns were sourced from the literature and official websites. Different scenarios were simulated to elicit break-even points between F-CGM and SMBG.
Results: The annual cost of SMBG with 3.7 tests per day (see REPLACE) is $180 per patient, compared to $2,156 incurred per F-CGM patient, representing a cost difference of $1,976/year or $5.41/day. This implies a budget break-even ratio of 1:12 patients (F-CGM:SMBG). Both technologies would break even at a consumption of 44 test strips per day. A year’s SMBG budget would last only 30 days if spent on F-CGM.
Conclusion: With diabetes budgets under pressure, thoughtful spending policies are needed. It is recommended to analyze in detail which T2DM subgroups will benefit most from F-CGM, focusing reimbursement to the latter. SMBG, being an established technology, represents - at current reimbursement levels - an attractive spending option to budget holders.

Disclosure
M. Stueve: Employee; Self; JnJ GmbH Life Scan. Y.F. Zoellner: Research Support; Self; J&J Medical GmbH, LifeScan.
Persistence of Allosensitization after Islet Allograft Failure
Authors: RIOS PAOLA , BAIDAL DAVID , PADILLA NATHALIA , ALVAREZ GIL ANA M. , MADIRAJU SRIGITA , AMBUT JONATHAN , MANTERO ALEJANDRO M. , RICORDI CAMILLO , ALEJANDRO RODOLFO 
Published: June 2018

Allosensitization (PRA+) has been reported after discontinuation of immunosuppression (IS) following graft failure (GF) in islet transplant (ITx) recipients. Persistence of PRA+ after GF is unknown.
Thirteen ITx alone (IA) and 5 ITx subjects who also received donor CD34+ hematopoietic stem cells (IBM) and developed GF enrolled in the study “Allosensitization After Islet Transplantation.” Panel reactive antibodies (PRA) were measured yearly while having graft function, within 1 year post-GF and yearly after study enrollment. Two subjects who developed GF but remained on mycophenolate mofetil (MMF) for 2 years and 18 subjects with persistent graft function (15 IA and 3 islet after kidney [IAK]) were also evaluated.
80% IBM subjects developed high PRA+ (&gt;89%) (Figure 1a) while 70% IA subjects were PRA+ at enrollment (0.8-6 years post-GF) and 42%-55% were PRA+ throughout follow-up. PRA results were variable (Figure 1b). The 2 subjects taking MMF post-GF and 1 subject who required IVIG pre-GF (for parvovirus infection) were not PRA+. Four subjects with persistent graft function by 10 years became PRA+ (2 IA and 2 IAK; Figure 1c).
After stopping IS, 70% IA subjects became PRA+ with persistence of PRA (although variable) for at least 10 years post-GF. PRA+ was higher in IBM compared to IA subjects. While receiving IS, PRA+ was minimal. Persistence of PRA+ remains a concern due to potentially prolonged wait list time for subsequent organ transplantation if needed.

Disclosure
P. Rios: None. D. Baidal: None. N. Padilla: None. A.M. Alvarez Gil: None. S. Madiraju: None. J. Ambut: None. A.M. Mantero: None. S. Messinger Cayetano: None. C. Ricordi: None. R. Alejandro: None.
The Skin Autofluorescence of Pregnant Women with Diabetes Predicts Macrosomia in Their Newborns
Authors: FOUSSARD NINON , HELMER CATHERINE , GONZALEZ CONCEPCION , BLANCO LAURENCE , MOHAMMEDI KAMEL , RIGALLEAU VINCENT 
Published: June 2018

Advanced Glycation End-products accumulated during long-term hyperglycaemia can be detected by measuring the Skin Autofluorescence (SAF). As pregestational and early gestational diabetes especially predispose to macrosomia, we sought whether the SAF of pregnant women with diabetes predicted macrosomia in their newborns. During years 2013-2015, we measured SAF (AGE-Reader, Diagnoptics, Groningen) at 25±7 weeks of amenorrhea in women with singleton pregnancies and diabetes. The birth weights and centiles according to gestational ages were recorded. Macrosomia was defined by birth weight ≥ 4000g and/or Large for Gestational Age ≥ 90 centile. The relation between SAF and macrosomia was tested by binary logistic regression analysis, adjusted for the other risk factors for macrosomia: maternal age and BMI, parity, and the type of diabetes (pregestational, early and late gestational diabetes mellitus). Two hundred and twelve women participated to the study: 16 pregestational, 75 early and 121 late gestational diabetes. They were 33±5 years old, their pregestational BMI were 27.2±6.9 kg/m2, and 1were nulliparous. The birth weights were 3160±550 g, and 23 newborns were macrosomic (10.8%). Mothers of macrosomic newborn had higher SAF: 2.04±0.31 AU vs. 1.83±0.34 for other mothers (p&lt;0.005). By binary logistic regression, the relation between SAF and macrosomia was significant (OR: 3.47; 95% CI: 1.01-11.86) after adjusting for maternal age (OR:1.13; 95% CI: 1.02-1.26) and for the type of diabetes (pregestational: OR: 5.97; 95% CI:1.51-23.54). This relation kept significant (OR: 4.21; 95% CI:1.13-15.67) after introducing the HbA1C in the model, available for 163 women. The skin autofluorescence, a marker of glycaemic memory, is higher in pregnant women with diabetes who will deliver a macrosomic newborn.

Disclosure
N. Foussard: None. C. Helmer: None. C. Gonzalez: None. L. Blanco: None. K. Mohammedi: Speaker's Bureau; Self; Novo Nordisk Inc.. Other Relationship; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Sanofi. Other Relationship; Self; Sanofi, Takeda Development Centre Europe Ltd., Boehringer Ingelheim Pharmaceuticals, Inc.. V. Rigalleau: None.
Glycemic Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in the Emirate of Dubai, United Arab Emirates—A Five-Year Pattern
Authors: ALAWADI FATHEYA , ABDELGADIR ELAMIN I.E. , BASHIER ALAAELDIN , HASSANEIN MOHAMED , RASHID FAUZIA , ALSAEED MARYAM , HAFIDH KHADIJA , ELSAYED MOHAMED , ABUELKHEIR SONA , FAROOQI MOHAMMED 
Published: June 2018

Background: In the United Arab Emirates (UAE) the comparative prevalence of diabetes is reported as 18.98%, but there are very few studies evaluating glycemic control.
Aims: Our primary aim was to assess the level of glycemic control across Dubai Health Authority (DHA) points of care over the past five years (2012-2016).
Methods: This audit is a retrospective analysis of the electronic medical records of all patients who attended the Dubai Health authority between 2012-2016.
Results and Discussion: A total of 26447 patients were included in the study making it the largest cohort of patients to be evaluated for diabetes control in the UAE. Out of those patients, UAE nationals were 73.8% (n=19508), while the other nationalities accounted for 26.2% (n=6939). The overall mean HbA1c from 2012 to 2016 was 7.76%. Patients attending primary care clinics had a mean HbA1c of 7.64%, compared to 7.68% for the tertiary care cohort. Out of the total population, 37.7% of them achieved HbA1c &lt;7%, while the majority (42.0%) had HbA1c of 7-9%, and only 20.3% of the total patient had an HbA1c &gt;9%. Upon comparing primary vs. tertiary patients who had HbA1c &lt;7, there were 40.79% and 34.87%, respectively. Moreover, the total percentage of patients with HbA1c &lt;9% were 80.53% and 79.24% in primary and tertiary setup, respectively.

Disclosure
F. Alawadi: None. E.I.E. Abdelgadir: None. A. Bashier: None. M. Hassanein: None. F. Rashid: None. M. Alsaeed: None. K. Hafidh: None. M. Elsayed: None. S. Abuelkheir: None. M. Farooqi: None.
In Early Pregnancy, a High Proportion of Women with Type 2 Diabetes Have Lower Daily Carbohydrate Consumption than Recommended by the Institute of Medicine
Authors: ÁSBJÖRNSDÓTTIR BJÖRG , RONNEBY HELLE , VESTGAARD MARIANNE , RINGHOLM LENE , JENSEN DORTE M. , RABEN ANNE , DAMM PETER , MATHIESEN ELISABETH R. 
Published: June 2018

Aim: Maternal glucose is the primary metabolic substrate for fetal growth and a diet low in carbohydrates is common among young women in the Western world. To secure sufficient carbohydrate consumption in pregnancy, the Institute of Medicine (IOM) recommends a minimum daily consumption of 175 grams of carbohydrates, corresponding to approximately 150 grams from the major carbohydrate sources. We aimed to explore the carbohydrate consumption in early pregnancy among women with type 2 diabetes and, for comparison, in women with type 1 diabetes.
Methods: As part of routine care, all pregnant women with type 2 and type 1 diabetes have since 2013 been asked to hand in a 3-day dietary record focusing on carbohydrates at their first antenatal visit. In the present study, total daily self-reported carbohydrate consumption from major carbohydrate sources, presence of ketonuria, HbA1c, weight and daily physical activity were evaluated.
Results: Dietary records were available from 96 women with type 2 diabetes vs. 1women with type 1 diabetes at median 71 (range 60-87) vs. 63 (56-76) gestational days (p=0.003) where HbA1c was 6.6 ±1.2% (49 ±13 mmol/mol) vs. 6.5 ±0.8% (48 ±8 mmol/mol) (P=0.8), respectively. Body weight was 90.8 (±22) vs. 75.5 (±15) kg (P&lt;0.001), but average daily carbohydrate consumption was similar in the two groups (159 ±56 vs. 167 ±48 g, P=0.3), as was the level of physical activity (246 ±104 vs. 233 ±96 metabolic equivalent of task (MET)-hour/week, P=0.5). A high proportion of the women consumed fewer carbohydrates than recommended by the IOM (52% vs. 40%, P=0.08). There was a low prevalence of ketonuria (&gt;4 mmol/L, equivalent to blood ketones of approx. 0.2 mmol/L) (2% vs. 1%, P=0.6).
Conclusion: In early pregnancy, women with type 2 diabetes had similar carbohydrate consumption to women with type 1 diabetes, despite higher body weight. Lower carbohydrate consumption than recommended by the IOM was prevalent, and ketonuria was rare.

Disclosure
B. ásbjörnsdóttir: None. H. Ronneby: None. M. Vestgaard: None. L. Ringholm: None. D.M. Jensen: None. A. Raben: None. P. Damm: Advisory Panel; Self; Novo Nordisk A/S. Other Relationship; Self; Novo Nordisk A/S. E.R. Mathiesen: Speaker's Bureau; Self; Novo Nordisk A/S. Other Relationship; Self; Novo Nordisk A/S, Novo Nordisk Foundation, Novo Nordisk A/S.
Gestational Diabetes and Diabetes and Prediabetes Risks Postpartum—A Large Observational Study
Authors: SHEN YUN , WANG PENG , WANG LEISHEN , ZHANG SHUANG , LIU HUIKUN , LI WEIQIN , LI NAN , LI WEI , LENG JUNHONG , WANG JING , TIAN HUIGUANG , ZHANG CUILIN , YANG XILIN , YU ZHIJIE M. , HU GANG 
Published: June 2018

The objective of this study was to compare risks of postpartum type 2 diabetes (T2D) and prediabetes in Chinese women with and without gestational diabetes (GDM) during pregnancy. Tianjin GDM observational study included 1263 women with a history of GDM and 7women without GDM who participated in the whole population’s GDM universal screening survey by using World Health Organization (WHO)’s criteria. Postpartum T2D and prediabetes were defined according to the American Diabetes Association (ADA) criteria after a standard oral glucose tolerance test. Cox proportional hazards regression was used to assess risks of postpartum T2D and prediabetes between women with and without GDM. During a mean follow-up of 3.53 years postpartum, 90 T2D and 599 prediabetes were identified. Multivariable-adjusted hazard ratios (HR) associated with GDM were 76.1 (95% CI 23.6-246) for T2D, and 25.4 (95% CI 18.2-35.3) for prediabetes. When a mean of follow-up extended to 4.40 years, 121 T2D and 616 prediabetes were identified. Women with prior GDM had a 13.0-fold increased risk (adjusted HR: 95% CI 5.54-30.6) for diabetes and 2.15-fold risk (95% CI 1.76-2.62) for prediabetes than women without GDM. The positive associations between GDM and the risks of postpartum T2D and prediabetes were significant and persistent across stratum by age at delivery (i.e., &lt; 30 years vs. &gt;= 30 years) and overall body adiposity status (i.e., normal vs. overweight). The present study among Chinese women indicated that women with prior GDM had a significantly increased risk for early postpartum T2D and prediabetes, with the risk being highest at the first 3 years postpartum, compared with those without GDM.

Disclosure
Y. Shen: None. P. Wang: None. L. Wang: None. S. Zhang: Employee; Self; American Diabetes Association. Advisory Panel; Self; Company/ABC. H. Liu: None. W. Li: None. N. Li: None. W. Li: None. J. Leng: None. J. Wang: None. H. Tian: None. C. Zhang: None. X. Yang: None. Z.M. Yu: None. G. Hu: None.
Vitamin D Status during Pregnancy and the Risk of Gestational Diabetes Mellitus—A Longitudinal Study in a Multiracial Cohort
Authors: XIA JIN , SONG YIQING , RAWAL SHRISTI , WU JING , HINKLE STEFANIE , TSAI MICHAEL Y. , ZHANG CUILIN 
Published: June 2018

Background: Emerging evidence suggests that vitamin D status in pregnancy may be associated with the development of gestational diabetes (GDM). However, the temporal relationship remains unclear due to the lack of prospective data with serial measurements of maternal vitamin D levels. We prospectively examined longitudinal changes in vitamin D biomarkers in relation to subsequent GDM risk.
Methods: A nested case-control study of 107 GDM cases and 214 controls (matched on age, race/ethnicity, and gestational week (GW) at blood draw) was conducted within the NICHD Fetal Growth Studies-Singleton Cohort (2009-2013). Plasma concentrations of D2 and D3 25-hydroxyvitamin D (25(OH)D) and vitamin D binding protein were measured at GWs 10-14, 15-26, 23-31, and 33-39; we further calculated total, free, and bioavailable 25(OH)D. Linear mixed-effects models and conditional logistic regression models were used adjusting for confounders.
Results: Compared with controls, women who developed GDM appeared to have lower concentrations of total 25(OH)D as early as GWs 10-14 (median: 25.59 vs. 27.46 ng/mL) and had a greater longitudinal increase in total 25(OH)D levels from GWs 10-14 to 15-26 (LS mean difference in log-scale: 0.10 vs. 0.04, p=0.046). We found no linear associations between vitamin D biomarkers at GWs 10-14 or GWs 15-26 and GDM risk. However, vitamin D deficiency (&lt;20 ng/mL) at GWs 10-14 was associated with a 2.82-fold increased GDM risk (adjusted OR=2.82, 95% CI: 1.15-6.93). Furthermore, women with persistent vitamin D deficiency at both weeks 10-14 and weeks 15-26 had more than 4-fold elevated risk for GDM compared to those persistently non-deficient (adjusted OR=4.46, 95% CI: 1.15-17.3).
Conclusions: Our findings suggest that maternal vitamin D deficiency in the first trimester of pregnancy may be implicated in the development of GDM. Assessment of vitamin D status in early pregnancy may be clinically important and valuable for the primary prevention of GDM.

Disclosure
J. Xia: None. Y. Song: None. S. Rawal: None. J. Wu: None. S. Hinkle: None. M.Y. Tsai: None. C. Zhang: None.
Postpartum Relapse in Diet Quality among Women Diagnosed with Gestational Diabetes
Authors: CHAKKALAKAL ROSETTE J. , HACKSTADT AMBER J. , SILVER HEIDI J. , ELASY TOM 
Published: June 2018

Background: Women with gestational diabetes (GDM) often improve their dietary intake during pregnancy to control hyperglycemia. Maintaining improved diet quality after delivery could reduce women’s risk of type 2 diabetes (T2DM) later in life.
Methods: We compared the diet quality of English and Spanish-speaking women diagnosed with GDM during vs. after pregnancy in this prospective cohort study. Study participants were contacted by telephone to complete two 24-hour diet recalls during pregnancy and 2 recalls after delivery. The alternative healthy eating index (AHEI) score was calculated from recall data to assess diet quality; higher scores indicate better diet quality. We compared the mean pregnancy AHEI score to the mean postpartum AHEI score for the sample. We then calculated the difference in mean pregnancy and postpartum AHEI scores for each participant, reported the mean difference in AHEI scores for the sample, and tested for significant differences using paired t-tests.
Results: Of the 38 participants who completed at least 1 pregnancy recall, 27 also completed at least 1 postpartum recall. Mean age of participants was 32.76+/-4.42 and mean BMI was 32.17+/-8.55. Half of the participants spoke Spanish. Medicaid and/or CHIP provided insurance coverage for 73.7% of participants. Medication was necessary to control hyperglycemia in 42.1% of participants. The mean pregnancy AHEI score was higher than the mean postpartum AHEI score (66.8+/- 11.2 vs. 60.3+/-12.9, respectively) for the sample. The mean difference in AHEI scores from pregnancy to postpartum was -6.96 (p=0.013). In a sensitivity analysis of participants completing all 4 recalls, the mean difference in AHEI scores was -7.03; the difference remained statistically significant (p=0.05).
Conclusions: GDM-affected women report significantly better diet quality during vs. after pregnancy. Efforts to prevent this postpartum relapse in diet quality could reduce rates of T2DM in this high-risk population.

Disclosure
R.J. Chakkalakal: None. A.J. Hackstadt: None. H.J. Silver: None. T. Elasy: None.
Association of First-Trimester Fasting Plasma Glucose with Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes
Authors: LI PING , LIN SHUO , LI LING , CUI JINHUI , FAN JIANHUI 
Published: June 2018

This study aims to evaluate the usefulness of a fasting plasma glucose (FPG) at the first trimester in predicting gestational diabetes mellitus (GDM) and the association between FPG and adverse pregnancy outcomes in Chinese women. Medical records of 2112 singleton pregnant women were collected from the third affiliated hospital of Sun Yat-Sen University, Guangzhou, China, from January 2016 to June 2017. FPG was measured at 9-13+6 weeks and 75 g oral glucose tolerance test (OGTT) was performed at 24-28 weeks in each subject. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria was used for diagnosing GDM. Among 2112 subjects, 224 (10.6%) subjects were diagnosed with GDM. The area under ROC curve (AUC) for FPG in predicting GDM was 0.63 (95% CI 0.61- 0.65) and the optimal cutoff value 4.5 mmol/L (sensitivity 64.29% and specificity 56.45%) (Figure 1). Higher first-trimester FPG increased the incidences of GDM, large for gestational age (LGA) and assisted vaginal delivery and/or cesarean section (all P &gt; 0.05). These results suggested FPG at first trimester could be used to predict GDM and higher first-trimester FPG was associated with adverse pregnancy outcomes.

Disclosure
P. Li: None. S. Lin: None. L. Li: None. J. Cui: None. J. Fan: None.